Inventor · disambiguated record
Yingnan Chen
Also filed as: CHEN YINGNAN · CHEN YINGNAN PAN
6 granted patents·6 pending applications·18 citations·filing 2001–2025
76Inventor score
Files withINCYTE CORP9
Top patents by PatentIndex Score
12 records- 0196US11427567B2Imidazolyl pyrimidinylamine compounds as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Aug 30, 2022·8 cites·22 claims
- 0294US11472791B2Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Oct 18, 2022·7 cites·31 claims
- 0391US11919904B2Sulfonylamide compounds as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Mar 5, 2024·3 cites·41 claims
- 0479US12466828B2Bicyclic amines as CDK2 inhibitorsINCYTE CORP·Filed 2023·Granted Nov 11, 2025·0 cites·47 claims
- 0578US2025243183A1Imidazolyl pyrimidinylamine compounds as cdk2 inhibitorsINCYTE CORP·Filed 2025·Application pending·0 cites
- 0675US12312331B2Imidazolyl pyrimidinylamine compounds as CDK2 inhibitorsINCYTE CORP·Filed 2022·Granted May 27, 2025·0 cites·35 claims
- 0775US2025059293A1Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapyINCYTE CORP·Filed 2024·Application pending·0 cites
- 0862US12060433B2CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapyINCYTE CORP·Filed 2020·Granted Aug 13, 2024·0 cites·39 claims
- 0949US2004077549A1Inhibitors of the E2F-1/cyclin interaction for cancer therapyFiled 2003·Application pending·0 cites
- 1048US2020316064A1Cyclin-dependent kinase 2 biomarkers and uses thereofINCYTE CORP·Filed 2020·Application pending·0 cites
- 1148US2004053849A1Inhibitors of the E2F-1/cyclin interaction for cancer therapyFiled 2003·Application pending·0 cites
- 1237US2002142966A1Inhibitors of the E2F-1/cyclin interaction for cancer therapyFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yingnan Chen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →